Table 1.
Clinical characteristics of diabetic individuals and non-diabetics from MASS-II Study.
Figure 1.
Kaplan-Meier Curves of combined T2DM risk alleles and composite cardiovascular end-point in non-diabetic individuals separated by groups according to number of risk alleles tertiles and diabetic subjects after 5 years of follow-up.
Note diabetic individuals' curves are similar to higher tertiles' curves. P values to pairwise comparisons: Lower vs middle: p = 0.052; lower vs higher: p = 0.002; lower vs diabetics: p = 0.001; middle vs higher: p = 0.178; middle vs diabetics: p = 0.101; higher vs diabetics: p = 0.870.
Table 2.
Number of composite cardiovascular events and cumulative hazard in diabetic subjects and non-diabetic subjects according to number of risk alleles tertiles.
Figure 2.
Kaplan-Meier curves for composite cardiovascular end-point in non-diabetic subjects separated by groups according to number of risk alleles tertiles and diabetic individuals, in accordance with the kind of treatment received (A - angioplasty, B - medical therapy or C - CABG).
Note for patients submitted to angioplasty, diabetic subjects and higher tertile non-diabetic individuals had higher end-point incidence.
Table 3.
Hazard ratio and 95% confidence interval (CI) for composite cardiovascular end-point and mortality according to each risk allele in the entire population and in diabetic and non-diabetic individuals.*
Figure 3.
Discriminatory ability for composite cardiovascular events of risk alleles and clinical risk factors in non-diabetic individuals.
ROC Curves for cardiovascular events in the MASS-II population. Observe an increased area under ROC curves (AUC or C statistic) after addition of information of combined risk alleles into clinical model for cardiovascular events. (*) Asymptotic significance: P value<0.00001. P values for comparisons between clinical model and mixed model (clinical and genetic model) = 0.03.